Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition.
On May10, 2017, Dimension Therapeutics, Inc. (the Company) issued
a press release regarding its financial and operating results for
the quarter ended March31, 2017. A copy of the Companys press
release is furnished as Exhibit 99.1 to this report on Form 8-K.
The following information and Exhibit 99.1 attached hereto shall
not be deemed filed for purposes of Section18 of the Securities
and Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, except as expressly set forth by specific
reference in such filing.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release issued by the Company on May 10, 2017, furnished herewith. |
About Dimension Therapeutics, Inc. (NASDAQ:DMTX)
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa. Dimension Therapeutics, Inc. (NASDAQ:DMTX) Recent Trading Information
Dimension Therapeutics, Inc. (NASDAQ:DMTX) closed its last trading session down -0.02 at 1.35 with 34,724 shares trading hands.
